FDA flags 4 deaths as potential safety signal for schizophrenia drug

The FDA has flagged four deaths among patients receiving Newron Pharmaceuticals’ investigational schizophrenia drug evenamide as a potential safety signal in its written explanation of a clinical hold on U.S. sites in a phase 3 trial. The four deaths occurred across all clinical studies of evenamide, compared with one death among patients receiving placebo, according […] The post FDA flags 4 deaths as potential safety signal for schizophrenia drug appeared first on Becker's Hospital...